Breakthrough Therapies for the Management of Eosinophilic Esophagitis: A Guide for Managed Care and Payer Professionals

Learn About:

• The clinical and economic burden of Eosinophilic Esophagitis (EoE)
• Current treatments for EoE and their limitations
• Emerging treatments for EoE
• The importance of early diagnosis of EoE and referral to an appropriate specialist

Expert Faculty Presenters:

Christina Barrington, PharmD VP of Pharmacy Programs Priority Health Click here for biography Evan S. Dellon, MD, MPH Professor of Medicine Adjunct Professor of Epidemiology Center for Esophageal Diseases and Swallowing Division of Gastroenterology and Hepatology University of North Carolina School of Medicine Click here for biography Mary Jo Strobel Executive Director APFED (American Partnership for Eosinophilic Disorders) Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
Managed care and payer professionals are well positioned to design and implement policies that have a considerable influence on EoE patient access to appropriate care. However, knowledge and competence are lacking on the value of early diagnosis and appropriate management of EoE including specialists’ referrals. In addition, these health care professionals lack knowledge of the clinical and economic burden of EoE and well as the limitations of current treatment options and the value of emerging therapies. Lastly, improved competence is needed to implement benefit designs that encourage timely initiation, modification, and monitoring of therapy.

Educational Objectives
After completing this activity, the participant should be better able to:

• Discuss the clinical and economic burden of eosinophilic esophagitis (EoE)
• Explain the importance of early diagnosis of EoE
• Review current treatment options for EoE and their limitations
• Assess the potential of emerging EoE therapies
• Apply strategies to ensure referral to an appropriate specialist to optimize EoE diagnosis and treatment

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Pharmacy Continuing Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-22-216-L01-P
Type of Activity: Knowledge

Please note: For Pharmacists: Upon completion of the online evaluation, you must use the Claim Credit link within the activity and select CPE credit to submit to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Faculty and Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Impact Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.